Login or sign up
For business
Average ratingGreat
4.3/ 5

Based on 10 reviews

550%
430%
320%
20%
10%
Ask AI

What reviewers say about Atrogi

Based on 10 reviews, listing data and website checks · updated 4 days ago

Customers describe Atrogi as professional, knowledgeable, and helpful, frequently praising the team's expertise, prompt support, and high-quality solutions.
What is Atrogi?

Atrogi is a Swedish pharmaceutical company based in Stockholm County that develops first-in-class oral GRK2-biased β₂-adrenergic modulators. Their platform focuses on turning muscle into medicine for conditions like muscle wasting and sarcopenia. The company aims to switch on muscle's metabolic machinery without the signaling liabilities that have blocked conventional β₂-drugs for nearly six decades.

What is ATR-258 and what did early human testing show?

The company's flagship product is ATR-258, an oral therapy designed to improve muscle function and body composition. Early human testing showed it reduced body fat while simultaneously increasing muscle mass. In an 8-week study, the drug was associated with an approximately 13% mean improvement in lower extremity muscle power combined with a beneficial effect on body composition.

Where is Atrogi located and what industry does it serve?

Atrogi is currently located in Solna, Sweden, with its headquarters at Tomtebodavägen 6, 5tr, 171 65 Solna. The company operates within the pharmaceutical industry and serves markets where muscle wasting and sarcopenia are significant health concerns. They have been active since at least 2022, as evidenced by their Trustburn reviews from that year.

What is the Trustburn rating and what do the reviews say?

The Trustburn rating for Atrogi is 4.3 out of 5 stars based on 10 reviews. The rating split shows a majority of 5-star ratings, with some 4-star and 3-star reviews included. Reviewers frequently praise the company's professionalism, prompt response to queries, and high-quality solutions.

What external news sources mention Atrogi?

According to news articles, Atrogi received backing from a €3 million European programme for their first-in-class drug targeting FSHD and other muscle-wasting diseases. The company also announced positive human data for ATR-258, which provided first human proof-of-mechanism and supported their planned Phase 2 trial.

What specific features does Atrogi highlight on its own website?

The company's website states that their oral compounds are once-daily and Phase II-ready. They describe their science as a balanced full agonist β₂AR signaling profile that avoids the liabilities of conventional β₂-drugs. The platform highlights their commitment to making muscle the center of health for metabolic and immune resilience.

What do reviewers specifically praise about Atrogi?

Some reviewers on Trustburn mention that Atrogi's team is highly knowledgeable and professional, helping them solve complex problems with ease. Others note that the company exceeded expectations in terms of quality and delivery, making them a go-to company for various needs.

What scientific approach does Atrogi use to address muscle wasting?

Atrogi's science platform focuses on GRK2-biased modulators that target muscle wasting. The company mentions that muscle loss is a critical issue, with power failing first, and their drugs aim to address this by switching on muscle's metabolic machinery.

What health statistics does Atrogi reference on its website?

The company's website references studies such as the PURE study and mentions that muscle loss increases the risk of death from any cause. They also highlight that up to 40% of weight lost on GLP-1 therapy is lean mass, which their drugs aim to counteract.

What development milestones has Atrogi achieved?

Atrogi's website mentions that they have granted patents and have thousands of compounds in their pipeline. The company also notes that their oral drugs are designed to be taken once daily, making them convenient for patients.

How can visitors contact Atrogi?

Atrogi's website includes a contact email, info@atrogi.com, for inquiries. The company also provides a physical address in Solna, Sweden, for those who prefer to mail correspondence or visit their offices.

What is the goal of Atrogi's research and development?

Atrogi's website highlights that their drugs are designed to improve muscle function and body composition. The company also mentions that they are working on a platform that can be used to explore the science of their compounds.

Is Atrogi on social media?

Atrogi has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Atrogi

Website
atrogi.com
Categories
Pharmaceuticals